Last reviewed · How we verify
Artesunate-amodiaquine drug combination
Artesunate-amodiaquine drug combination is a Small molecule drug developed by University of Yaounde 1. It is currently FDA-approved. Also known as: Coarsucam.
At a glance
| Generic name | Artesunate-amodiaquine drug combination |
|---|---|
| Also known as | Coarsucam |
| Sponsor | University of Yaounde 1 |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa (PHASE4)
- Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya
- A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines (PHASE3)
- A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs. (PHASE3)
- In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in Mozambique (PHASE4)
- Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 (PHASE2)
- Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial (PHASE2, PHASE3)
- Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Artesunate-amodiaquine drug combination CI brief — competitive landscape report
- Artesunate-amodiaquine drug combination updates RSS · CI watch RSS
- University of Yaounde 1 portfolio CI
Frequently asked questions about Artesunate-amodiaquine drug combination
What is Artesunate-amodiaquine drug combination?
Artesunate-amodiaquine drug combination is a Small molecule drug developed by University of Yaounde 1.
Who makes Artesunate-amodiaquine drug combination?
Artesunate-amodiaquine drug combination is developed and marketed by University of Yaounde 1 (see full University of Yaounde 1 pipeline at /company/university-of-yaounde-1).
Is Artesunate-amodiaquine drug combination also known as anything else?
Artesunate-amodiaquine drug combination is also known as Coarsucam.
What development phase is Artesunate-amodiaquine drug combination in?
Artesunate-amodiaquine drug combination is FDA-approved (marketed).
Related
- Manufacturer: University of Yaounde 1 — full pipeline
- Also known as: Coarsucam
- Compare: Artesunate-amodiaquine drug combination vs similar drugs
- Pricing: Artesunate-amodiaquine drug combination cost, discount & access